GTx shares dive as clot threat brings FDA clinical hold for prostate cancer product
22 February 2012
Nancy Faigen
Please Login to read the full article.
22 February 2012
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- GTx raises $47.5 M to advance Ostarine in cancer-wasting and partner Capesaris
- Iron chelator, prostate cancer conundrum on deck for ODAC
- GTx lowers dose in attempt to lift hold on prostate cancer drug
- ODAC backs ApoPharma's iron chelator, but lacks harmony on prostate cancer trials
FEATURES
Other Informa Features
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
